CDKN2A and mantle cell lymphoma: To identify a potential strategy for the treatment of R/R MCL, we performed cytotoxicity screening of inhibitors targeting DDR and cell cycle promotors in MCL cell lines with various mutations in ATM, TP53, and CDKN2A (Fig. 1c).